Selen Gozde Kaya, Gokcen Eren, Alberto Massarotti, Filiz Bakar-Ates, Erva Ozkan, Mahmut Gozelle, Yesim Ozkan
{"title":"2-(甲基(苯基)氨基)-N-(苯氧基苯基)乙酰胺结构基团代表选择性抑制 SIRT2 的框架。","authors":"Selen Gozde Kaya, Gokcen Eren, Alberto Massarotti, Filiz Bakar-Ates, Erva Ozkan, Mahmut Gozelle, Yesim Ozkan","doi":"10.1002/ddr.22224","DOIUrl":null,"url":null,"abstract":"<p>The mammalian cytoplasmic protein SIRT2, a class III histone deacetylase family member, possesses NAD<sup>+</sup>-dependent lysine deacetylase/deacylase activity. Dysregulation of SIRT2 has been implicated in the pathogenesis of several diseases, including neurological and metabolic disorders and cancer; thus, SIRT2 emerges as a potential therapeutic target. Herein, we identified a series of diaryl acetamides (<b>ST61</b>-<b>ST90</b>) by the structural optimization of our hit <b>STH2</b>, followed by enhanced SIRT2 inhibitory potency and selectivity. Among them, <b>ST72</b>, <b>ST85</b>, and <b>ST88</b> selectively inhibited SIRT2 with IC<sub>50</sub> values of 9.97, 5.74, and 8.92 μM, respectively. Finally, the entire study was accompanied by <i>in silico</i> prediction of binding modes of docked compounds and the stability of SIRT2-ligand complexes. We hope our findings will provide substantial information for designing selective inhibitors of SIRT2.</p>","PeriodicalId":11291,"journal":{"name":"Drug Development Research","volume":"85 4","pages":""},"PeriodicalIF":3.5000,"publicationDate":"2024-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ddr.22224","citationCount":"0","resultStr":"{\"title\":\"2-(Methyl(phenyl)amino)-N-(phenyloxyphenyl)acetamide structural motif representing a framework for selective SIRT2 inhibition\",\"authors\":\"Selen Gozde Kaya, Gokcen Eren, Alberto Massarotti, Filiz Bakar-Ates, Erva Ozkan, Mahmut Gozelle, Yesim Ozkan\",\"doi\":\"10.1002/ddr.22224\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>The mammalian cytoplasmic protein SIRT2, a class III histone deacetylase family member, possesses NAD<sup>+</sup>-dependent lysine deacetylase/deacylase activity. Dysregulation of SIRT2 has been implicated in the pathogenesis of several diseases, including neurological and metabolic disorders and cancer; thus, SIRT2 emerges as a potential therapeutic target. Herein, we identified a series of diaryl acetamides (<b>ST61</b>-<b>ST90</b>) by the structural optimization of our hit <b>STH2</b>, followed by enhanced SIRT2 inhibitory potency and selectivity. Among them, <b>ST72</b>, <b>ST85</b>, and <b>ST88</b> selectively inhibited SIRT2 with IC<sub>50</sub> values of 9.97, 5.74, and 8.92 μM, respectively. Finally, the entire study was accompanied by <i>in silico</i> prediction of binding modes of docked compounds and the stability of SIRT2-ligand complexes. We hope our findings will provide substantial information for designing selective inhibitors of SIRT2.</p>\",\"PeriodicalId\":11291,\"journal\":{\"name\":\"Drug Development Research\",\"volume\":\"85 4\",\"pages\":\"\"},\"PeriodicalIF\":3.5000,\"publicationDate\":\"2024-06-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ddr.22224\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Drug Development Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/ddr.22224\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Development Research","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/ddr.22224","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
2-(Methyl(phenyl)amino)-N-(phenyloxyphenyl)acetamide structural motif representing a framework for selective SIRT2 inhibition
The mammalian cytoplasmic protein SIRT2, a class III histone deacetylase family member, possesses NAD+-dependent lysine deacetylase/deacylase activity. Dysregulation of SIRT2 has been implicated in the pathogenesis of several diseases, including neurological and metabolic disorders and cancer; thus, SIRT2 emerges as a potential therapeutic target. Herein, we identified a series of diaryl acetamides (ST61-ST90) by the structural optimization of our hit STH2, followed by enhanced SIRT2 inhibitory potency and selectivity. Among them, ST72, ST85, and ST88 selectively inhibited SIRT2 with IC50 values of 9.97, 5.74, and 8.92 μM, respectively. Finally, the entire study was accompanied by in silico prediction of binding modes of docked compounds and the stability of SIRT2-ligand complexes. We hope our findings will provide substantial information for designing selective inhibitors of SIRT2.
期刊介绍：
Drug Development Research focuses on research topics related to the discovery and development of new therapeutic entities. The journal publishes original research articles on medicinal chemistry, pharmacology, biotechnology and biopharmaceuticals, toxicology, and drug delivery, formulation, and pharmacokinetics. The journal welcomes manuscripts on new compounds and technologies in all areas focused on human therapeutics, as well as global management, health care policy, and regulatory issues involving the drug discovery and development process. In addition to full-length articles, Drug Development Research publishes Brief Reports on important and timely new research findings, as well as in-depth review articles. The journal also features periodic special thematic issues devoted to specific compound classes, new technologies, and broad aspects of drug discovery and development.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
